IL205257A - Isolated monoclonal antibody associated with the epitope of a respiratory syncytial virus strain a2 virus and various aspects related to this antibody - Google Patents

Isolated monoclonal antibody associated with the epitope of a respiratory syncytial virus strain a2 virus and various aspects related to this antibody

Info

Publication number
IL205257A
IL205257A IL205257A IL20525710A IL205257A IL 205257 A IL205257 A IL 205257A IL 205257 A IL205257 A IL 205257A IL 20525710 A IL20525710 A IL 20525710A IL 205257 A IL205257 A IL 205257A
Authority
IL
Israel
Prior art keywords
seq
positions
region consisting
fragment
rsv
Prior art date
Application number
IL205257A
Other languages
English (en)
Hebrew (he)
Other versions
IL205257A0 (en
Original Assignee
Trellis Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trellis Bioscience Inc filed Critical Trellis Bioscience Inc
Publication of IL205257A0 publication Critical patent/IL205257A0/en
Publication of IL205257A publication Critical patent/IL205257A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
IL205257A 2007-10-25 2010-04-22 Isolated monoclonal antibody associated with the epitope of a respiratory syncytial virus strain a2 virus and various aspects related to this antibody IL205257A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46907P 2007-10-25 2007-10-25
US8940108P 2008-08-15 2008-08-15
PCT/US2008/081175 WO2009055711A2 (en) 2007-10-25 2008-10-24 Anti-rsv g protein antibodies

Publications (2)

Publication Number Publication Date
IL205257A0 IL205257A0 (en) 2010-12-30
IL205257A true IL205257A (en) 2014-12-31

Family

ID=40580419

Family Applications (1)

Application Number Title Priority Date Filing Date
IL205257A IL205257A (en) 2007-10-25 2010-04-22 Isolated monoclonal antibody associated with the epitope of a respiratory syncytial virus strain a2 virus and various aspects related to this antibody

Country Status (14)

Country Link
US (3) US7736648B2 (https=)
EP (1) EP2214711B1 (https=)
JP (2) JP5808536B2 (https=)
KR (1) KR101671452B1 (https=)
CN (1) CN101808663B (https=)
AU (1) AU2008316703B2 (https=)
BR (1) BRPI0819210A2 (https=)
CA (1) CA2703667C (https=)
IL (1) IL205257A (https=)
MX (1) MX2010004482A (https=)
NZ (1) NZ585589A (https=)
RU (1) RU2526517C2 (https=)
WO (1) WO2009055711A2 (https=)
ZA (1) ZA201003131B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003298738A1 (en) * 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
WO2009055711A2 (en) * 2007-10-25 2009-04-30 Trellis Bioscience, Inc. Anti-rsv g protein antibodies
WO2013095091A2 (en) 2011-11-17 2013-06-27 Aimm Therapeutics B.V. Rsv g protein specific antibodies
US10131709B2 (en) 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
WO2013098420A1 (en) * 2011-12-28 2013-07-04 Immunoqure Ag Method of isolating human antibodies
WO2013119419A1 (en) 2012-02-08 2013-08-15 North Carolina State University Treatment of allergic diseases with recombinant antibodies
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
CN111303278B (zh) * 2013-04-15 2022-09-06 扬森疫苗与预防公司 结合到rsv g蛋白的人类抗体
EA035846B1 (ru) * 2013-04-15 2020-08-20 Янссен Вэксинс Энд Превеншн Б.В. Антитела человека, связывающиеся с g-белком rsv
US10196438B2 (en) 2013-04-15 2019-02-05 Janssen Vaccines & Prevention B.V. Human antibodies binding to RSV G protein
EP3105250B1 (en) * 2014-02-10 2020-08-05 IGM Biosciences, Inc. Iga multi-specific binding molecules
CN103911389A (zh) * 2014-04-09 2014-07-09 南昌大学 一种检测人呼吸道合胞病毒抗体的g和f蛋白的制备方法
BR112017011932A8 (pt) 2014-12-05 2022-11-08 Memorial Sloan Kettering Cancer Center Anticorpos direcionados a receptor acoplado a proteína g e métodos de uso
CN118271463A (zh) 2014-12-05 2024-07-02 纪念斯隆-凯特琳癌症中心 靶向g-蛋白偶联受体的嵌合抗原受体及其用途
CN106496324B (zh) * 2015-11-30 2020-01-14 天津昊免生物技术有限公司 一种抗呼吸道合胞病毒的全人源抗体
CN105542003B (zh) * 2016-03-01 2019-12-06 苏州博泰神州生物技术有限公司 一种针对rsv粘附g蛋白表面抗原的全人源单克隆抗体
WO2018089335A1 (en) 2016-11-09 2018-05-17 North Carolina State University Treatment of allergic diseases with chimeric protein
EP3573651A4 (en) 2017-01-27 2020-10-14 NGM Biopharmaceuticals, Inc. GLUCAGON RECEPTOR BINDING PROTEINS AND METHODS OF USE
CA3079604A1 (en) * 2017-10-13 2019-04-18 Trellis Bioscience, Llc Conformational epitopes in respiratory syncytial virus g protein central conserved region
US12060437B2 (en) 2018-03-23 2024-08-13 North Carolina State University Methods and compositions for antibody to high affinity receptor for IgE
EP3829636A1 (en) 2018-07-27 2021-06-09 NGM Biopharmaceuticals, Inc. Use of glucagon receptor antagonists with immunotherapeutic agent
EP3833677A4 (en) * 2018-08-08 2022-04-27 Trellis Bioscience, Inc. IMPROVED RSV PASSIVE AND ACTIVE VACCINES
EP3932424A4 (en) 2019-02-28 2022-10-12 KM Biologics Co., Ltd. Rsv f/g chimeric vaccine
WO2021046384A1 (en) 2019-09-06 2021-03-11 Silgan White Cap LLC Tethered, hinged closure
EP4031171A1 (en) * 2019-09-20 2022-07-27 Universiteit Antwerpen A novel human respiratory syncytial virus strain and its use
EP4069742A1 (en) 2019-12-06 2022-10-12 Juno Therapeutics, Inc. Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
EP4429966A4 (en) 2021-11-08 2026-01-14 Silgan White Cap LLC PROJECTION ON THE NECK OF A CONTAINER
EP4566632A1 (en) * 2022-08-02 2025-06-11 Nona Biosciences (Suzhou) Co., Ltd. Msln antibody-drug conjugate
WO2025106427A1 (en) * 2023-11-14 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
WO2025194126A1 (en) * 2024-03-15 2025-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Respiratory syncytial virus (rsv) g and f antibodies with high rsv-neutralizing potency

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69426077T3 (de) * 1993-05-25 2004-09-02 Wyeth Holdings Corp. Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
FR2766192B1 (fr) * 1997-07-17 2001-07-13 Pf Medicament Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
US6642062B2 (en) 1998-09-03 2003-11-04 Trellis Bioinformatics, Inc. Multihued labels
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
WO2000043040A1 (en) 1999-01-22 2000-07-27 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Methods for the prevention and treatment of diseases caused by an inflammatory response mediated by endogenous substance p by using anti-substance p antibodies
CA2426312C (en) * 2000-10-18 2014-01-14 Ralph A. Tripp Compositions and methods for modulating rsv infection and immunity
US7413868B2 (en) 2003-11-05 2008-08-19 Trellis Bioscience, Inc. Use of particulate labels in bioanalyte detection methods
JP4736037B2 (ja) * 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CN1986569A (zh) * 2005-12-23 2007-06-27 首都儿科研究所 人源抗呼吸道合胞病毒中和性基因工程Fab抗体
WO2007094423A1 (ja) 2006-02-15 2007-08-23 Evec Incorporated ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分
WO2007101441A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
CA2657123A1 (en) 2006-07-12 2008-01-17 Trellis Bioscience, Inc. Cellspottm applications
WO2009055711A2 (en) * 2007-10-25 2009-04-30 Trellis Bioscience, Inc. Anti-rsv g protein antibodies

Also Published As

Publication number Publication date
KR101671452B1 (ko) 2016-11-17
WO2009055711A2 (en) 2009-04-30
CN101808663B (zh) 2015-09-30
US20100285022A1 (en) 2010-11-11
EP2214711A2 (en) 2010-08-11
KR20100091195A (ko) 2010-08-18
RU2526517C2 (ru) 2014-08-20
JP2015078231A (ja) 2015-04-23
US20130034564A1 (en) 2013-02-07
EP2214711A4 (en) 2011-12-21
US20090130120A1 (en) 2009-05-21
BRPI0819210A2 (pt) 2015-06-23
RU2010120879A (ru) 2011-11-27
AU2008316703A2 (en) 2010-07-22
AU2008316703B2 (en) 2012-09-27
MX2010004482A (es) 2010-07-06
US7736648B2 (en) 2010-06-15
AU2008316703A1 (en) 2009-04-30
JP2011500091A (ja) 2011-01-06
EP2214711B1 (en) 2018-08-15
CA2703667C (en) 2015-12-29
NZ585589A (en) 2012-07-27
US9321830B2 (en) 2016-04-26
IL205257A0 (en) 2010-12-30
CA2703667A1 (en) 2009-04-30
ZA201003131B (en) 2011-03-30
US8273354B2 (en) 2012-09-25
CN101808663A (zh) 2010-08-18
WO2009055711A3 (en) 2009-09-24
JP5808536B2 (ja) 2015-11-10

Similar Documents

Publication Publication Date Title
IL205257A (en) Isolated monoclonal antibody associated with the epitope of a respiratory syncytial virus strain a2 virus and various aspects related to this antibody
US9073999B2 (en) Anti-IL-17 receptor A neutralizing antibodies
EA034767B1 (ru) Человеческие антитела к белку f респираторного синцитиального вируса и способы их применения
MXPA06004853A (es) Anticuerpos que se aglutinan al receptor 4 de interleucina.
JP2012509881A5 (https=)
CA3232651A1 (en) Antibodies to canine interleukin-4 receptor alpha
RU2012112829A (ru) Анти-gitr-антитела
CA2420231A1 (en) Antibodies to human il-1.beta.
CN110642944A (zh) 一种中和人感染h7n9甲型流感病毒的抗体及其用途
TR201808486T4 (tr) Bradikinin B1 reseptör ligandlarına karşı antikorlar.
CN114644708B (zh) 呼吸道合胞病毒特异性结合分子
CN110732023B (zh) 一种her2抗体药物组合物及其用途
TWI865727B (zh) 一種抗il-4r抗體醫藥組成物及其用途
EP4353744A1 (en) Antibody against respiratory syncytial virus and use thereof
KR20220091566A (ko) 항il-4r 단일 도메인 항체 및 이의 응용
CN110960490A (zh) 一种抗egfr抗体偶联药物组合物及其用途
TWI869137B (zh) 廣譜新型冠狀病毒的雙特異性抗體
CN117098777A (zh) 一种tslp抗原结合蛋白及其应用
JP2018529328A5 (https=)
CA2525657A1 (en) Human monoclonal antibody specific for lipopolysaccharides (lps) of serotype iats o6 of pseudomonas aeruginosa
AU2022404234A1 (en) Antibody for recognizing rsv pre-f protein and use thereof
EP4257603A1 (en) Pharmaceutical composition comprising anti-connective tissue growth factor antibody
CN119119253A (zh) 靶向结合腮腺炎病毒的抗体或其抗原结合片段
JP2022513671A (ja) Ｃｄ４０抗体医薬品組成物およびその使用
JP2022516439A5 (https=)

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees